As of July 10, 2025, Beijing Hotgen Biotech Co Ltd (688068.SS) reports a Current Ratio of 5.48.
Current Ratio assesses a company's ability to pay short-term debts by comparing liquid assets to liabilities, with higher ratios signaling better financial health.
Historical Trend of Beijing Hotgen Biotech Co Ltd's Current Ratio
Over recent years, Beijing Hotgen Biotech Co Ltd's Current Ratio has shown significant volatility. The table below summarizes the historical values:
| Date | Current Ratio |
|---|---|
| 2024-12-31 | 5.48 |
| 2023-12-31 | 4.47 |
| 2022-12-31 | 3.52 |
| 2021-12-31 | 3.43 |
| 2020-12-31 | 4.08 |
This fluctuation highlights how Beijing Hotgen Biotech Co Ltd manages its short-term assets and liabilities over time.
Comparing Beijing Hotgen Biotech Co Ltd's Current Ratio to Peers
To better understand Beijing Hotgen Biotech Co Ltd's position, it's useful to compare its Current Ratio against industry peers. Below are selected comparisons:
| Company | Current Ratio |
|---|---|
| Beijing Hotgen Biotech Co Ltd (688068.SS) | 5.48 |
| Abnova Taiwan Corp (4133.TW) | 14.95 |
| Celestial Biolabs Ltd (CELESTIAL.NS) | 13.72 |
| Aligned Genetics Inc (238120.KQ) | 13.48 |
| NanoEnTek Inc (039860.KQ) | 12.79 |
| Genetic Signatures Ltd (GSS.AX) | 10.04 |
Compared to its competitors, Beijing Hotgen Biotech Co Ltd's Current Ratio is among the highest compared to peers, indicating strong short-term financial flexibility but potentially excess cash that could be invested.